A new roadmap outlining key priorities for tuberculosis vaccine research and development for the next 10 years is now available.
The blueprint, which was published March 20 in the journal Tuberculosis, was endorsed and sponsored by the World Health Organization-led Stop TB Partnership Working Group on New Vaccines. It is designed to inform donors, the public and affected stakeholders that “there is now a global effort to do something about this terrible disease,” SciDev.Net says.
The blueprint identifies five priorities for the tuberculosis vaccine research community: enable creativity in research, achieve a better understanding of the infectious disease, improve coordination of late-stage clinical trials, develop quicker and more innovative ways to test vaccine efficacy, and promote more rapid development.
Further, the roadmap proposes the creation of global criteria for choosing the best vaccine candidates and calls for greater advocacy and media engagement to build political support for research and development.
Read more development aid news online, and subscribe to The Development Newswire to receive top international development headlines from the world’s leading donors, news sources and opinion leaders — emailed to you FREE every business day.
About the author
Ivy Mungcal
As senior staff writer, Ivy Mungcal contributes to several Devex publications. Her focus is on breaking news, and in particular on global aid reform and trends in the United States, Europe, the Caribbean and the Americas. Before joining Devex in 2009, Ivy produced specialized content for U.S. and U.K.-based business websites.
